In conclusion, the low specificity of p16/Ki67 immunostaining found in HIV-infected patients indicates that this technique might hardly prove to be cost-efficient for anal cancer screening in HIV-infected subjects. This evidence concerns the gene MKI67 and anal carcinoma.